Measuring holotranscobalamin II, an early indicator of negative vitamin B12 balance, by radioimmunoassay in patients with ischemic cerebrovascular disease

Basit Öğe Kaydı
dc.contributor.authorSerefhanoglu, Songul
dc.contributor.authorAydogdu, Ismet
dc.contributor.authorKekilli, Ersoy
dc.contributor.authorIlhan, Atilla
dc.contributor.authorKuku, Irfan
dc.date.accessioned2024-08-04T20:30:45Z
dc.date.available2024-08-04T20:30:45Z
dc.date.issued2008
dc.departmentİnönü Üniversitesien_US
dc.description.abstractCirculating homocysteine is a risk factor of cardiovascular and cerebrovascular events. Hyperhomocysteinemia may be an early indicator for vitamin B-12 disorders because cobalamin is a cofactor in the remethylation process of homocysteine. Serum holotranscobalamin (holoTC II) becomes decreased before the development of metabolic dysfunction. In this study, we assessed circulating holoTC II to estimate the diagnosis of vitamin B-12 deficiency in the first ischemic cerebrovascular attack. We also compared the efficacy of the measurement of plasma holoTC II with the other standard biochemical and hematological markers used to reach the diagnosis of cobalamin deficiency. Forty-five patients (age 71 years (range 35-90), 16 men/29 women) within the first ischemic cerebrovascular event were included in this prospective study. All the enrolled patients have been administered vitamin B-12 1 mg intramuscular injection once a day for 10 days. At the baseline and on the tenth day of treatment, plasma levels of holoTC II and the proper biochemical and hematological markers in diagnosing cobalamin deficiency were measured. After admission, anemia and diminished serum vitamin B-12 levels were determined to be only 20% (9/45) and 44% (20/45), respectively; 78% (35/45) of the patients had low serum holoTC II (< 37 pmol/l). Serum homocysteine was higher in patients (49% of them) who had previously suffered a stroke. Thrombocytopenia, hypersegmentated neutrophils, and indirect hyperbilirubinemia were observed in 20% of the patients. Leukopenia and macrocytosis were not evident in any of them. In 18 of 27 patients (67%) that had low holoTC II levels after joining the study and who remained in the study until the end of cobalamin treatment, serum holoTC II levels returned to normal values. Cobalamin deficiency should be considered in patients with cerebrovascular diseases, even if anemia, elevated mean cell volume, depression of the serum cobalamin, or other classic hematological and/or biochemical abnormalities are lacking. Furthermore, measurement of serum holoTC II looks promising as a first-line of tests for diagnosing early vitamin B-12 deficiency.en_US
dc.identifier.doi10.1007/s00277-007-0406-3
dc.identifier.endpage395en_US
dc.identifier.issn0939-5555
dc.identifier.issn1432-0584
dc.identifier.issue5en_US
dc.identifier.pmid17992530en_US
dc.identifier.scopus2-s2.0-41549150365en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage391en_US
dc.identifier.urihttps://doi.org/10.1007/s00277-007-0406-3
dc.identifier.urihttps://hdl.handle.net/11616/94495
dc.identifier.volume87en_US
dc.identifier.wosWOS:000254360000008en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.relation.ispartofAnnals of Hematologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectholotranscobalamin IIen_US
dc.subjectvitamin B-12 deficiencyen_US
dc.subjectischemic cerebrovascular diseaseen_US
dc.titleMeasuring holotranscobalamin II, an early indicator of negative vitamin B12 balance, by radioimmunoassay in patients with ischemic cerebrovascular diseaseen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu